Comment
Author: Admin | 2025-04-28
And repeat courses of moderately emetogenic cancer chemotherapy.Postoperative nausea and/or vomiting: IV, IM, Oral: Prevention of postoperative nausea and/or vomiting (PONV). If nausea/vomiting occur in a patient who had not received prophylactic ondansetron, IV ondansetron may be administered to prevent further episodes.Limitations of use: Routine prophylaxis for PONV in patients with minimal expectation of nausea and/or vomiting is not recommended, although use is recommended in patients when nausea and vomiting must be avoided in the postoperative period, even if the incidence of PONV is low.Radiotherapy-associated nausea and vomiting: Oral: Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Use: Off LabelCarcinoid syndrome-associated diarrhea, severe, refractorycData from a limited number of patients (case reports) suggest that ondansetron may be of benefit in the management of severe carcinoid syndrome associated-diarrhea that is refractory to preferred agents (eg, somatostatin analogues) Kiesewetter 2013, Platt 1992, Schwörer 1995, Wymenga 1998.Gastroparesis, symptomatic treatment of nausea and vomiting (alternative agent in patients with persistent symptoms refractory to prokinetic therapy)cExpert opinion suggests the utility of ondansetron as an alternative agent in patients with persistent nausea and vomiting refractory to prokinetic therapy ACG [Camilleri 2013], Camilleri 2018. There are no published data evaluating the role of antiemetics, including ondansetron, in the treatment of this condition.Nausea and/or vomiting, acute, severecLimited data from a small number of randomized and nonrandomized trials, primarily in the emergency department setting, suggest benefit with ondansetron in the treatment of severe, acute undifferentiated nausea and/or vomiting Barrett 2011, Braude 2008, Egerton-Warburton 2014, Patka 2011, Salvucci 2011; however, definitive, high-quality trials supporting efficacy are lacking Furyk 2015.Clinical experience also suggests the utility of ondansetron in the treatment of severe, acute nausea and vomiting due to a variety of self-limiting etiologies such as viral gastroenteritis Alexandraki 2019, acute mountain sickness Gallagher 2018, or a variety of other medical conditions associated with severe nausea/vomiting.Postoperative nausea and vomiting, treatment or rescue therapyyesBased on the Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea, it is reasonable to administer a 5-HT3 receptor antagonist for the treatment of postoperative nausea and vomiting when a prophylactic agent was not utilized or as rescue therapy when an agent from a different class was utilized as prophylaxis and failed.Pregnancy-associated nausea and vomiting, severe or refractorybyesBased on the Society of Obstetricians and Gynaecologists of Canada guideline on nausea and vomiting of pregnancy and the American College of Obstetricians and Gynecologists practice bulletin, the use of ondansetron may be considered in the treatment of severe or refractory nausea and vomiting when preferred agents have failed ACOG 2018, Arsenault 2002.Vertigo-associated nausea and vomitingcData from a small, open-label, pilot study and clinical experience suggests the utility of ondansetron in the acute treatment of nausea and vomiting associated with vertigo Furman 2018, Rice 1995. ContraindicationsHypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine Dosage and AdministrationDosing: AdultNote: Single IV doses >16 mg are no longer recommended
Add Comment